MentionFox
Home › Executive changes › Astria Therapeutics, Inc.
Leadership changes · ATXS · SEC Form 8-K, Item 5.02

Leadership changes at Astria Therapeutics, Inc. (2026)

Before you join, sell to or invest in Astria Therapeutics, Inc.

MentionFox check on Astria Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/astria-therapeutics

Check Astria Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Astria Therapeutics, Inc.?

Who joined and who left Astria Therapeutics, Inc. (ATXS)? 1 filing reported on 2026-01-23, each cited to the company's own filing.

As of November 14, 2026, Astria Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 23, 2026 (Form 8-K, January 23, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

ForGrowth III PA B.V. also filed stake reports on 4 other companies ↓

Sell to companies like Astria Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-01-23

Astria Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-23. Every row below is cited to the filing it comes from, and this page adds each new change as Astria Therapeutics, Inc. files it.

Also on the record for Astria Therapeutics, Inc.

DateRecordFigureOur pageSource
February 17, 2026Stake report, Schedule 13G/A, by Vestal Point Capital, LP—5%+ stakesSource
February 12, 2026Stake report, Schedule 13G/A, by Glazer Capital, LLC6.61% of the class5%+ stakesSource
February 9, 2026Stake report, Schedule 13D/A, by Perceptive Advisors LLC—5%+ stakesSource
January 28, 2026Stake report, Schedule 13D/A, by Magnetar Financial LLC—5%+ stakesSource
December 10, 2025Stake report, Schedule 13G, by Glazer Capital, LLC5.53% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by ForGrowth III PA B.V.—5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Vestal Point Capital, LP8.8% of the class5%+ stakesSource
November 7, 2025Stake report, Schedule 13G/A, by FMR LLC2.2% of the class5%+ stakesSource
November 5, 2025Stake report, Schedule 13G/A, by FMR LLC9.1% of the class5%+ stakesSource
October 24, 2025Stake report, Schedule 13D, by Magnetar Financial LLC5.87% of the class5%+ stakesSource
October 20, 2025Stake report, Schedule 13G/A, by Millennium Management LLC0.4% of the class5%+ stakesSource
October 16, 2025Stake report, Schedule 13D/A, by Perceptive Advisors LLC11.5% of the class5%+ stakesSource

Selling to them or working with them? See who runs Astria Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Astria Therapeutics, Inc. and the records around it.

Astria Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Astria Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Astria Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Astria Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-23Reportednot named in the filing8-K, 2026-01-23
Selling to Astria Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Astria Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Astria Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Astria Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Astria Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-01-23 · 8-K

Reported

As a result of the Merger and pursuant to the terms of the Merger Agreement, effective as of the Effective Time, (i) each of Kenneth Bate, Sunil Agarwal, M.D., Joanne T. Beck, Ph.D., Fred Callori, Hugh M. Cole, Michael D. Kishbauch, Gregg Lapointe, Jill C. Milne, Ph.D., and Jonathan Violin, Ph.D., resigned from their respective positions as directors of Astria and from all committees of the board of directors of Astria on which such directors served, and (ii) each of Jill C. Milne, Ph.D., Noah Clauser, CPA, Andrew A. Komjathy, Chris Morabito, M.D., Ben Harshbarger, J.D., and Andrea Matthews re

Also stated in this filing

  • From and after the Effective Time and pursuant to the terms of the Merger Agreement, (i) Babar Ghias and Alane Barnes (the directors of Merger Sub immediately prior to the Effective Time) have become the directors of Astria and (ii) the following individuals became the executive officers of Astria: Babar Ghias as the President and Alane Barnes as the Secretary, in each of the foregoing cases until successors are duly elected or appointed and qualified in accordance with Astria's certificate of incorporation and bylaws and applicable law.

Tools for this story

Each opens in a new tab, filled in for Astria Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/astria-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Astria Therapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/astria-therapeutics